Infected Thrombus of the Bioprosthetic Aortic Valve with Distal Arterial Embolization after 3 Years of Valve Replacement Surgery

Jung Ae Hong, Sung-Ai Kim
Division of Cardiology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea

Current guidelines recommend the use of warfarin in the first 3 months after bioprosthetic valve replacement and suggest long-term anticoagulation only in patients with obvious risk factors for thrombosis. Despite at low risk of thromboembolism, we present a case of a 72-year-old male patient with infected thrombus at bioprosthetic aortic valve with distal arterial embolization after 3 years of replacement surgery. The incidence of asymptomatic bioprosthetic valve thrombosis (BPVT) may be higher than anticipated and active surveillance echocardiography is needed to early detect BPVT before leading to fatal complication.

Keywords: Infection; Thrombosis; Endocarditis; Bioprosthesis; Aortic valve

INTRODUCTION

The overall rate of bioprosthetic valve thrombosis (BPVT) is 0.03% per year [1] and late valve thrombosis of Mosaic porcine prosthesis is 0.1% to 0.3% per patient-year [2,3]. It is a comparatively rare complication, but the sequelae may be fatal. For the antithrombotic therapy of bioprosthetic valve, the American College of Cardiology/American Heart Association (ACC/AHA) guidelines [4] recommend the use of warfarin for at least 3 months and as long as 6 months after bioprosthetic aortic valve replacement (AVR) and suggest long-term anticoagulation only in patients with obvious risk factors for thrombosis as history of thromboembolism, hypercoagulable conditions, left ventricular dysfunction, and ongoing atrial fibrillation. Herein, we present a case of a 72-year-old male patient at a low risk of thromboembolism presenting an infected thrombus at bioprosthetic aortic valve (AV) with distal arterial embolization after 3 years of replacement surgery.

CASE REPORT

A 72-year-old man was admitted to Hallym Sacred Heart Hospital with poor oral intake, fever, and chills for 2 weeks. He had a history of hypertension and had undergone bioprosthetic AVR (23 mm Medtronic Mosaic porcine prosthesis) for degenerative AV stenosis 3 years ago. Postoperatively, the patient was anticoagulated with warfarin for 6 months and has taken aspirin until admission. Physical examination disclosed a grade of 2/6 systolic ejection murmur at the aortic area and a blood pressure of 150/90 mm Hg, heart rate 95 beats/min, and a temperature of 38.5°C. Electrocardiography showed sinus rhythm with right bundle branch block and chest radiography showed no cardiomegaly. Laboratory studies yielded the following results: white blood cell 19.6 × 10^3/μL (normal reference range, 4 to 10 × 10^3/μL); hemoglobin 13.8 g/dL (normal reference range, 14 to 17 g/dL); platelet 165 × 10^3/μL (normal reference range, 130 to 450 × 10^3/μL); C-reactive protein 135 mg/L (normal reference range, 0 to 5 mg/L); lactate dehydrogenase 674 IU/L (normal reference range, 240 to 460 IU/L); and B-type natriuretic peptide level 256 pg/mL (normal reference value ≤160 pg/mL).

Transthoracic echocardiography (TTE) revealed a 1.3 × 1.4-cm-sized mobile mass attached to bioprosthetic AV (left ventricular side) with an increased transvalvular gradient (max/mean 77/50 mm Hg) (Fig. 1A, B) and a decrease in calculated AV area 0.6 cm². Transesophageal echocardiography provided no more informa-
Infected Thrombus of the Bioprosthetic Aortic Valve

Hong JA, et al.

Soonchunhyang Medical Science 21(2):180-183

http://jsms.sch.ac.kr

181

Infected Thrombus of the Bioprosthetic Aortic Valve
Hong JA, et al.

Soochunhyang Medical Science 21(2):180-183
http://jsms.sch.ac.kr

181
weeks, the patient was uneventful and follow-up TTE showed a decrease in transvalvular gradient (max/mean, 77/50 to 49/29 mm Hg), although there was no size variation of thrombus (1.3 × 1.4 cm). At fourth week of anticoagulation, follow-up TTE showed no more thrombus and normalization of transvalvular gradient (max/mean, 49/29 to 29/17 mm Hg) and calculated AV area (0.60 to 1.45 cm²) (Fig. 3A, B). To summarize, the patient received 2 weeks of double antibiotic therapy followed by 4 weeks of intravenous ceftriaxone and anticoagulation therapy. No bleeding or other adverse events occurred during that period. He was discharged with maintaining oral warfarin and remained asymptomatic for 3 months.

**DISCUSSION**

This is the first complicated case of infected thrombus at bioprosthetic AV after 3 years of replacement surgery. Based on the initial presentation, the mobile mass at bioprosthetic AV was regarded as vegetation because of the obvious infection signs and clarifying the mass either vegetation or thrombus with echocardiography was challenging. We were lack of awareness for the coexistence of thrombus until the distal arterial embolization occurred. Despite the absence of histologic confirmation in this case, there is high probability of adhesion of microorganism on the platelet-fibrin obstructive thrombus at bioprosthetic AV with high velocity jet.

Current ACC/AHA and European Society of Cardiology guidelines recommend annual echocardiography beginning 5 years after replacement surgery or when patients become symptomatic or valve dysfunction is suspected [4,5]. However, the occurrence of BPVT in this patient at low risk for thromboembolism and the published cases diagnosed as BPVT on aspirin therapy in which the mean interval of BPVT was 13 months (range, 7 to 47 months) after replacement surgery [6-9], suggest the true incidence of asymptomatic BPVT may be higher than anticipated and stress the necessity of routine annual echocardiography for the first 5 years of post replacement surgery.

The initial standard therapy for left-sided prosthetic valve thrombosis has been surgery or thrombolysis [4]. However, in hemodynamically stable patients, anticoagulation with vitamin K antagonist (VKA) could be a safe and effective treatment precluding re-do valve operation in patients with obstructive thrombosis at bioprosthetic AV [6,9,10]. In this case, although thrombus is comparatively larger in size (1.4 × 1.4 cm), VKA showed sustained improvement of transvalvular gradient and nearly resolution of thrombus for a month, which verified VKA as first-line therapy in
clinically stable patients with BPVT. Despite of no histologic findings, complete resolution of infection signs and thrombus after antibiotics therapy and anticoagulation confirmed the presence of infective thrombus in this patient. When the mean transvalvular gradient was increased early after valve replacement surgery, differential diagnosis of infective thrombus as well as thrombus and vegetation per se is required with integration of clinical and echocardiographic findings.

REFERENCES